Author

R. Dumpit

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

E. Corey· 2 shared P. S. Nelson· 2 shared A. Bankhead· 1 shared A. G. Sowalsky· 1 shared A. Mariani· 1 shared A. N. Alilin· 1 shared A. T. Ku· 1 shared B. Hanratty· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Corey

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

S. Frank, T. Persse, I. M. Coleman, A. Bankhead, D. Li, N. DeSarkar, D. Wilson, D. Rudoy, M. Vashisth, P. Galipeau, M. Yang, B. Hanratty, R. Dumpit, c. Morrissey, E. Corey, , P. S. Nelson

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

bioRxiv · Jul 16, 2024 · PreprintCancer Biology

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

S. Agarwal, L. Fang, K. McGowen, J. Yin, J. Bowman, A. N. Alilin, A. T. Ku, E. Corey, M. Roudier, L. True, R. Dumpit, I. Coleman, J. Lee, P. S. Nelson, B. J. Capaldo, , K. Kelly

This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.

bioRxiv · Apr 19, 2022 · PreprintCancer Biology